The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 18, 2021
Filed:
Dec. 13, 2013
Applicant:
Canadian Blood Services, Ottawa, CA;
Inventors:
Assignee:
CANADIAN BLOOD SERVICES, Ottawa, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 35/17 (2015.01); A61K 31/7105 (2006.01); A61K 35/15 (2015.01); A61K 35/26 (2015.01); C12N 5/0783 (2010.01); C12N 5/078 (2010.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/7105 (2013.01); A61K 35/15 (2013.01); A61K 35/26 (2013.01); C12N 5/0636 (2013.01); C12N 5/0648 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12N 2500/50 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1178 (2013.01);
Abstract
This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.